Seres Therapeutics Investors Anticipate Exciting Updates
Seres Therapeutics, Inc. (NASDAQ: MCRB) has announced an important event for investors and stakeholders. On a designated date, the company will hold a conference call as well as a live audio webcast. The primary objective will be to discuss financial results for the second quarter of 2025 and share vital business updates.
Details of the Conference Call
To participate in the upcoming conference call, interested individuals can dial in at a designated time. Domestic callers can reach the line at 800-715-9871, while those calling internationally should use 646-307-1963. When calling, it's essential to reference the conference ID number provided by the company.
Webcast Access and Replay
For those who prefer to join online, the live webcast will be available through the 'Investors and News' section on the company's official website. Approximately two hours post-event, a replay of the presentation will also be accessible, remaining available for a duration of roughly 21 days.
Meet Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ: MCRB) is not just another clinical-stage company. It's at the forefront of revolutionizing patient outcomes, especially within medically fragile groups, through innovative live biotherapeutics. They have achieved remarkable milestones, including the creation of VOWST™, the first orally administered microbiome therapeutic approved by the FDA. In a significant business move, this product was sold to Nestlé Health Science.
Currently, the focus is on developing SER-155, aimed at preventing bloodstream infections among adults who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapeutic candidate has gained recognition for its potential, having received Breakthrough Therapy designation for several application areas. The progress in clinical trials is promising, showcasing a substantial reduction in infection-related risks.
Pipeline and Future Directions
Seres Therapeutics is not resting on its laurels. Beyond SER-155, the company has a diverse pipeline targeting various disease pathways relevant to patients in need. These future plans include therapies for not only allo-HSCT recipients but also for individuals battling cancer, chronic liver disease, and those recovering from solid organ transplants.
In addition, there’s a strategic vision towards evaluating these candidates in specialized medical settings, including intensive care units and long-term acute care facilities, making a deeper impact on vulnerable patient groups.
Contact Information
Investor relations and media contacts can reach out directly to the team at Seres Therapeutics. For inquiries, you can email IR@serestherapeutics.com, or contact Carlo Tanzi, Ph.D. at Kendall Investor Relations through the email catanzi@kendallir.com. These channels are open for anyone looking to connect regarding the latest developments or to gain further insights about the company.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call is aimed at discussing Seres Therapeutics' second quarter 2025 financial results and providing essential business updates to investors.
How can I join the conference call?
You may join the conference call by dialing in using the provided numbers and referencing the conference ID number.
Will there be a replay of the conference call available?
Yes, a replay will be available on the Seres website approximately two hours after the live event and will be archived for about 21 days.
What is SER-155?
SER-155 is a therapeutic candidate under development by Seres Therapeutics, focused on minimizing the risk of infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
How does Seres Therapeutics impact patient care?
By providing innovative live biotherapeutics, Seres Therapeutics aims to improve health outcomes, particularly for patients in vulnerable medical situations.
